The Test Differentiates Squamous From Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous-Cell Carcinoma of the Lung With Sensitivity of 96 Percent and Specificity of 90 Percent - This is the First CLIA Approved Test Which Leverages MicroRNAs' Sensitivity as Biomarkers for Accurate Diagnosis of Lung Cancer - July 22 , 2008- Rosetta Genomics, Ltd. (NASDQ: ROSG) announces that the first molecular test based on Rosetta Genomics' proprietary microRNA technology, developed and validated by Columbia University Medical Center (CUMC), has been approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program. CUMC is now finalizing the commercial aspects of this test and will announce its clinical availability to patients nationwide once details are finalized later this year... Rosetta Genomics' Press Release -
